https://www.jnj.com/rss-feed/all.rss RSS feed all en-US Mon, 27 Apr 2026 20:33:30 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-bernsteins-42nd-annual-strategic-decisions-conference Mon, 27 Apr 2026 20:33:30 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-bernsteins-42nd-annual-strategic-decisions-conference https://www.jnj.com/media-center/press-releases/fda-grants-priority-review-for-imaavy-nipocalimab-aahu-as-the-potential-first-approved-treatment-for-people-living-with-warm-autoimmune-hemolytic-anemia-waiha Priority Review is granted to medicines that may offer significant improvements in safety or effectiveness for serious conditions like warm autoimmune hemolytic anemia, a life-threatening disease in which pathogenic immunoglobulin G autoantibodies attach to and destroy red blood cells, leading to debilitating anemia IMAAVY is designed to target the underlying cause of warm autoimmune hemolytic anemia by reducing circulating immunoglobulin G, including autoantibodies, while preserving critical immune functions Pivotal study showed rapid and durable hemoglobin responsea and fatigue improvementb compared to placebo in patients with warm autoimmune hemolytic anemia Mon, 27 Apr 2026 12:18:35 GMT https://www.jnj.com/media-center/press-releases/fda-grants-priority-review-for-imaavy-nipocalimab-aahu-as-the-potential-first-approved-treatment-for-people-living-with-warm-autoimmune-hemolytic-anemia-waiha https://www.jnj.com/media-center/press-releases/fda-approves-caplyta-lumateperone-snda-with-robust-new-data-supporting-reduced-risk-of-relapse-in-schizophrenia CAPLYTA® reduced relapse risk by 63 percent, with 84 percent of patients with schizophrenia relapse-free over six months Demonstrating long-term stability and a well-established safety profile consistent with previous CAPLYTA® studies Mon, 27 Apr 2026 12:16:06 GMT https://www.jnj.com/media-center/press-releases/fda-approves-caplyta-lumateperone-snda-with-robust-new-data-supporting-reduced-risk-of-relapse-in-schizophrenia https://www.jnj.com/media-center/press-releases/johnson-johnson-enters-agreement-to-acquire-atraverse-medical Fri, 24 Apr 2026 12:30:57 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-enters-agreement-to-acquire-atraverse-medical https://www.jnj.com/media-center/press-releases/johnson-johnson-launches-landmark-head-to-head-pulsed-field-ablation-trial-in-persistent-atrial-fibrillation The PERSIGMA randomized control trial will deliver comparative evidence on the safety and effectiveness of the investigational VARIPULSE Pro and FARAPULSE1 platforms Fri, 24 Apr 2026 11:45:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-launches-landmark-head-to-head-pulsed-field-ablation-trial-in-persistent-atrial-fibrillation https://www.jnj.com/media-center/press-releases/imaavy-nipocalimab-aahu-shows-over-two-years-of-sustained-disease-control-in-a-broad-population-with-generalized-myasthenia-gravis-gmg Through 120 weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+ Patients achieving sustained minimal symptom expression (MSE) experienced greater improvements in quality of life than those with transient MSE in a post-hoc analysis of the Phase 3 study EPIC, the first head-to-head study of IMAAVY versus another FcRn blocker in generalized myasthenia gravis, is now enrolling participants Wed, 22 Apr 2026 12:05:00 GMT https://www.jnj.com/media-center/press-releases/imaavy-nipocalimab-aahu-shows-over-two-years-of-sustained-disease-control-in-a-broad-population-with-generalized-myasthenia-gravis-gmg https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-ce-mark-approval-for-the-new-ethicon-4000-stapler Designed to elevate the surgical experience and deliver reliable staple line integrity across a broad range of tissue thickness1* the ETHICON™ 4000 Surgical Stapler is certified for use in open and laparoscopic surgery across specialities in the European Union. • ETHICON™ 4000, the advanced surgical stapler, features ETHICON™ 3D Reloads with proprietary 3D Stapling Technology and enhanced Gripping Surface Technology to manage various tissues across specialties, including bariatric, colorectal and thoracic surgeries • 3D stapling technology is designed to optimize compression not only underneath each staple but also across staples and multiple staple lines, including both stapled and unstapled regions of the tissue2 • New ETHICON™ advanced stapling technology to be harnessed for future use on the OTTAVA™ Robotic Surgical System Wed, 22 Apr 2026 11:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-ce-mark-approval-for-the-new-ethicon-4000-stapler https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-2026-rbc-capital-markets-global-healthcare-conference Tue, 21 Apr 2026 20:23:09 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-2026-rbc-capital-markets-global-healthcare-conference https://www.jnj.com/media-center/press-releases/johnson-johnson-showcases-carto-powered-innovation-including-debut-of-cartosound-sonata-to-advance-arrhythmia-care-at-hrs-2026 As Johnson & Johnson celebrates 30 years of CARTO, the launch of CARTOSOUND SONATA brings new AI-based imaging and mapping capabilitiesi to electrophysiology A total of 17 abstracts will be presented, including new clinical data for the VARIPULSE Platform Tue, 21 Apr 2026 11:45:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-showcases-carto-powered-innovation-including-debut-of-cartosound-sonata-to-advance-arrhythmia-care-at-hrs-2026 https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-bank-of-america-2026-healthcare-conference Wed, 15 Apr 2026 20:07:44 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-bank-of-america-2026-healthcare-conference https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-64th-consecutive-year-of-dividend-increase-raises-quarterly-dividend-by-3-1 Tue, 14 Apr 2026 10:21:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-64th-consecutive-year-of-dividend-increase-raises-quarterly-dividend-by-3-1 https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q1-2026-results-raises-2026-outlook • 2026 First-Quarter reported sales growth of 9.9% to $24.1 Billion with operational growth of 6.4%* and adjusted operational growth of 5.3%* • 2026 First-Quarter earnings per share (EPS) of $2.14 and adjusted EPS of $2.70 • Company increases 2026 guidance with estimated reported sales of $100.8 Billion or 7.0% at the midpoint, and adjusted EPS4 of $11.55 or 7.1% at the midpoint • Solidifying path to double-digit growth by the end of the decade, with significant progress for patients with the approvals of ICOTYDE the first-and-only targeted oral peptide for plaque psoriasis, TECVAYLI plus DARZALEX FASPRO as early as second line for patients with relapsed/refractory multiple myeloma, VARIPULSE Pro in Europe with a new pulse sequence that is now 5 times faster, and TECNIS PureSee Intraocular Lens for U.S. Cataract Patients • Company announces planned Enterprise Business Review for December 8, 2026 Tue, 14 Apr 2026 10:20:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q1-2026-results-raises-2026-outlook https://www.jnj.com/media-center/press-releases/johnson-johnson-highlights-favorable-12-month-interim-results-for-the-varipulse-platform-at-ehra-2026 VARIPURE, a SECURE substudy, is the largest prospective real-world dataset for the VARIPULSE Pulsed Field Ablation Platform Results presented demonstrate high effectiveness, strong safety, and workflow versatility across diverse patient populationsi. Mon, 13 Apr 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-highlights-favorable-12-month-interim-results-for-the-varipulse-platform-at-ehra-2026 https://www.jnj.com/media-center/press-releases/johnson-johnson-showcases-new-clinical-data-for-tecnis-puresee-iol-at-ascrs-2026-demonstrating-excellent-contrast-sensitivity-and-extended-range-of-vision Robust clinical data, spans two major studies across U.S., Europe and Asia Pacific Data reveals TECNIS PureSee IOL achieved exceptional distance and intermediate vision, low bothersome visual symptoms, high tolerance to post-op refractive errors High patient satisfaction results with TECNIS PureSee IOL Fri, 10 Apr 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-showcases-new-clinical-data-for-tecnis-puresee-iol-at-ascrs-2026-demonstrating-excellent-contrast-sensitivity-and-extended-range-of-vision https://www.jnj.com/media-center/press-releases/johnson-johnson-advances-pulsed-field-ablation-portfolio-with-the-launch-of-varipulse-pro-in-europe The VARIPULSE Pro Platform features a new pulse sequence designed to streamline procedures and enhance workflow efficiencyi,ii VARIPULSE Pro to be featured at EHRA 2026 alongside VARIPURE 12-month interim data Tue, 07 Apr 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-advances-pulsed-field-ablation-portfolio-with-the-launch-of-varipulse-pro-in-europe https://www.jnj.com/media-center/press-releases/inlexzo-gemcitabine-intravesical-system-assigned-permanent-billing-code-supporting-access-for-patients-with-certain-bladder-cancers · INLEXZO permanent J-code (J9183) effective April 1 Wed, 01 Apr 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/inlexzo-gemcitabine-intravesical-system-assigned-permanent-billing-code-supporting-access-for-patients-with-certain-bladder-cancers https://www.jnj.com/media-center/press-releases/stemi-dtu-randomized-control-trial-demonstrates-for-the-first-time-that-a-combination-of-delayed-reperfusion-and-left-ventricular-unloading-does-not-increase-myocardial-infarct-size Sat, 28 Mar 2026 16:08:06 GMT https://www.jnj.com/media-center/press-releases/stemi-dtu-randomized-control-trial-demonstrates-for-the-first-time-that-a-combination-of-delayed-reperfusion-and-left-ventricular-unloading-does-not-increase-myocardial-infarct-size https://www.jnj.com/media-center/press-releases/icotyde-icotrokinra-one-year-results-confirm-lasting-skin-clearance-and-favorable-safety-profile-in-once-daily-pill-for-plaque-psoriasis Johnson & Johnson presents new data showing high rates of complete skin clearance achieved at Week 24 and Week 52 in ICONIC-ADVANCE 1 and 2 studies Nearly 60% of adolescents treated with ICOTYDE achieved completely clear skin at Week 52 in the ICONIC-LEAD study Sat, 28 Mar 2026 14:33:53 GMT https://www.jnj.com/media-center/press-releases/icotyde-icotrokinra-one-year-results-confirm-lasting-skin-clearance-and-favorable-safety-profile-in-once-daily-pill-for-plaque-psoriasis https://www.jnj.com/media-center/press-releases/fda-approval-of-icotyde-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pill ICOTYDE offers an innovative new option for patients with moderate-to-severe plaque psoriasis to address patients cycling on topical therapies in need of systemic treatment Wed, 18 Mar 2026 12:04:56 GMT https://www.jnj.com/media-center/press-releases/fda-approval-of-icotyde-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide https://www.jnj.com/media-center/press-releases/johnson-johnson-highlights-promising-first-in-human-erda-idrs-formerly-tar-210-results-in-intermediate-risk-non-muscle-invasive-bladder-cancer · Data presented at EAU 2026 show an 89 percent complete response rate in intermediate‑risk disease with durable responses observed over 18 months and tolerable safety profile · Erda-iDRS has the potential to be the first targeted treatment for early‑stage bladder cancer Fri, 13 Mar 2026 16:46:47 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-highlights-promising-first-in-human-erda-idrs-formerly-tar-210-results-in-intermediate-risk-non-muscle-invasive-bladder-cancer https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-fda-approval-of-tecnis-puresee-intraocular-lens-a-breakthrough-solution-for-u-s-cataract-patients • 97% of patients reported no very bothersome visual disturbances, like halos or glare, with TECNIS PureSee IOL1 • 97% of patients would recommend this IOL to friends or family2 • TECNIS PureSee IOL is the first and only U.S. FDA-approved extended depth of focus (EDOF) IOL maintaining contrast sensitivity comparable to an aspheric monofocal IOL1* Thu, 12 Mar 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-fda-approval-of-tecnis-puresee-intraocular-lens-a-breakthrough-solution-for-u-s-cataract-patients https://www.jnj.com/media-center/press-releases/tecvayli-teclistamab-monotherapy-application-submitted-to-the-ema-for-relapsed-refractory-multiple-myeloma-after-at-least-one-prior-therapy Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy1 Teclistamab monotherapy delivered superior progression-free survival and overall survival versus standard of care, reducing the risk of disease progression or death by 71% in a high unmet need patient population2 Tue, 10 Mar 2026 11:55:05 GMT https://www.jnj.com/media-center/press-releases/tecvayli-teclistamab-monotherapy-application-submitted-to-the-ema-for-relapsed-refractory-multiple-myeloma-after-at-least-one-prior-therapy https://www.jnj.com/media-center/press-releases/european-commission-approves-akeega-niraparib-and-abiraterone-acetate-dual-action-tablet-for-the-treatment-of-patients-with-brca1-2-mutated-metastatic-hormone-sensitive-prostate-cancer-mhspc Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall survival versus standard of care1 Approximately one in ten patients with mHSPC harbour BRCA1/2 alterations, reinforcing the need for new targeted treatment options2 Expanded indication for niraparib and abiraterone acetate delivers a precision-based treatment approach for this patient population1 Mon, 09 Mar 2026 17:01:55 GMT https://www.jnj.com/media-center/press-releases/european-commission-approves-akeega-niraparib-and-abiraterone-acetate-dual-action-tablet-for-the-treatment-of-patients-with-brca1-2-mutated-metastatic-hormone-sensitive-prostate-cancer-mhspc https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-u-s-fda-approval-of-tecvayli-plus-darzalex-faspro-for-relapsed-refractory-multiple-myeloma-offering-a-potential-new-standard-of-care-as-early-as-second-line Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression‑free survival and overall survival versus standard of care regimens 83.3% of patients were alive at three years, indicating durable clinical benefit Thu, 05 Mar 2026 20:30:20 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-u-s-fda-approval-of-tecvayli-plus-darzalex-faspro-for-relapsed-refractory-multiple-myeloma-offering-a-potential-new-standard-of-care-as-early-as-second-line https://www.jnj.com/media-center/press-releases/johnson-johnson-therapy-nipocalimab-granted-u-s-fda-fast-track-designation-in-systemic-lupus-erythematosus-sle Fast Track designation reflects the unmet need in this serious disease and enables the potential for an accelerated FDA review timeline The designation is supported by a Phase 2 study in which nipocalimab demonstrated reduction in lupus disease activity and potential for steroid sparing Systemic lupus erythematosus is a debilitating, chronic autoantibody-driven disease affecting multiple organs, with limited treatment options and risk of irreversible organ damage Johnson & Johnson is actively enrolling patients in a Phase 3 study of adults with active systemic lupus erythematosus Tue, 03 Mar 2026 13:05:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-therapy-nipocalimab-granted-u-s-fda-fast-track-designation-in-systemic-lupus-erythematosus-sle